Pages

Tuesday, June 19, 2012

Study: Majority Of Kidney Cancer Patients Prefer Pazopanib Over Sunitinib.

MedPage Today Share to FacebookShare to Twitter (6/3, Susman) reported that according to research presented at the American Society of Clinical Oncology meeting, "Researchers said...they were stunned by the clear preference for treatment with the targeted agent pazopanib (Votrient) over sunitinib (Sutent) for treatment of metastatic renal cell carcinoma. For the primary endpoint in the study – patient preference, 70% of patients in the double-blind, crossover study, opted for treatment with pazopanib, compared with 22% of the patients preferring treatment with sunitinib (P<0.001)."
        HealthDay Share to FacebookShare to Twitter (6/3, Dallas) reported that approximately "60 percent of physicians preferred Votrient, while 21 percent opted for Sutent and 21 percent had no preference."

No comments:

Post a Comment